LRMR
Larimar Therapeutics
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Larimar Therapeutics reported positive open-label data and submitted the first module of its rolling BLA for NomlabofuspJun 29, 2026
- Larimar Therapeutics secures FDA Breakthrough Therapy designation for nomlabofusp in Friedreich’s ataxia and reaffirms planned BLA submission in June 2026Feb 24, 2026
- Larimar Therapeutics announces positive data from ongoing long-term open-label study and updates to Nomlabofusp program for Friedreich's ataxiaSep 29, 2025
- Larimar Therapeutics receives FDA recommendations on safety database and BLA submission details for nomlabofusp in Friedreich's ataxiaJun 23, 2025